Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escalated Application of MSCs in ALS
NCT02987413Phase 1Completed
- Sponsor
- Hospital e Maternidade Dr. Christóvão da Gama
- Start
- Apr 2015
- Primary completion
- Mar 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous mesenchymal stem cells in amyotrophic lateral sclerosis (ALS), sponsored by Hospital e Maternidade Dr. Christóvão da Gama. Primary endpoint: Serious Adverse Events at 12 months. Started Apr 2015; status: completed.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02987413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02987413.